Pipeline - Takeda Oncology

Our Pipeline

Pipeline

Our Pipeline

Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational therapy

Platform

Investigational indication

Phase

Cabozantinib*

Targeted therapy

Metastatic castration-resistant prostate cancer (JP)

Phase 3

Ixazomib*

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU)

Phase 3

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN)

Phase 3

Mobocertinib*

Targeted therapy

2L EGFR Exon20 insertion non-small cell lung cancer (JP)

Phase 3

Targeted therapy

1L EGFR Exon20 insertion non-small cell lung cancer

Phase 3

Ponatinib*

Targeted therapy

FL Ph+ acute lymphocytic leukemia (US)

Phase 3

Targeted therapy

Pediatric Ph+ acute lymphoblastic leukemia

Phase 1

Relugolix* (TAK-385)

Small molecule

Prostate cancer (JP, Asian countries)

Phase 3

Niraparib*

Targeted therapy

Triple-negative breast cancer

Phase 3

Modakafusp Alfa (TAK-573)

I-O cold-to-hot

Multiple myeloma

Phase 1/2

I-O cold-to-hot

Solid tumors

Phase 1/2

Subasumstat (TAK-981)

I-O cold-to-hot

Solid tumors

Phase 1/2

I-O cold-to-hot

Non-Hodgkin lymphoma

Phase 1/2

I-O cold-to-hot

Multiple myeloma

Phase 1/2

TAK-007

I-O redirected immunity

B-cell malignancies

Phase 2

TAK-186

I-O redirected immunity

Solid tumors

Phase 1/2

TAK-102

I-O redirected immunity

Solid tumors

Phase 1

TAK-103

I-O redirected immunity

Solid tumors

Phase 1

TAK-500

I-O cold-to-hot

Solid tumors

Phase 1

TAK-676

I-O cold-to-hot

Solid tumors

Phase 1

TAK-940

I-O redirected immunity

B-cell malignancies

Phase 1

TAK-280

I-O redirected immunity

Solid tumors

Phase 1/2

Takeda Oncology Pipeline

*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets